TSA Pre-Signing Review
Quantify the regulatory exposure before signing.
Fixed-fee proposal in 48 hours. Senior team on day one. The first conversation is always free.
A biotech and pharma carve-out TSA carries regulated workflows that consumer or industrial deals do not. GxP validated systems, clinical trial sponsorship, regulatory submissions, batch record continuity, manufacturing licences, and pharmacovigilance reporting all sit inside the service catalog. The work runs inside the broader carve-out advisory framework with life sciences specific overlays that change the timeline, the controls, and the exit ramp. The buyer that ignores the regulatory layer in pre-signing finds the cost in a delayed approval, a paused trial, or a manufacturing site put on hold.
Good Manufacturing Practice, Good Laboratory Practice, and Good Clinical Practice systems all carry validation packages under FDA 21 CFR Part 11 and EMA Annex 11. The seller's quality management system, electronic batch record system, laboratory information management system, electronic data capture system, document management system, and trial master file system all sit in scope. The Newco cannot just lift and shift these systems. Each requires either a continued validated state in the destination tenant, or a fresh validation effort if the move involves a new instance.
The TSA usually keeps the seller hosting validated systems for an extended period. Revalidation cost and timeline are the dominant drivers of TSA duration in life sciences deals. A buyer who insists on a fast exit may incur revalidation costs that exceed the extension fees for several quarters of TSA service. The economic decision needs to be made with the validation lead, the regulatory affairs team, the head of quality, and the CFO in the room.
When the validated system migrates, installation qualification, operational qualification, and performance qualification all require fresh evidence on the destination tenant. Audit trail continuity has to be preserved with cryptographic linkage between source and destination records. The pattern overlaps with the broader TSA exit data migration strategy playbook.
Clinical trial sponsorship transfer is the most sensitive workstream in a biotech carve-out. Active investigational new drug applications, clinical trial authorisations, study protocols, investigator agreements, and trial master files all reference the seller as sponsor. The transfer of sponsorship requires regulatory authority notification, typically thirty days in advance for FDA and longer for EMA, plus institutional review board notifications at every site.
The trial master file has to travel with full audit integrity. Every document, every version, every signature, and every quality control record has to land on the Newco side complete. A trial master file with documentation gaps after transfer will fail an inspection and the trial may be paused. Most carve-outs run the trial master file under TSA hosting until the sponsorship transfer is fully complete and the validation of the destination archive has been signed off.
Clinical site relationships need their own communication plan. Investigators, study coordinators, and contract research organisations need to know the new sponsor, the new payment routing, the new safety reporting contact, and the timing of any system changes. The pattern overlaps with the broader Day One customer and vendor communication playbook.
Every product the Newco will own carries a regulatory submission lifecycle. New Drug Applications, Biologics License Applications, Marketing Authorisation Applications, supplements, variations, and annual reports all reference the seller as the responsible applicant. The transfer requires a sequence of regulatory filings to update the holder of record at FDA, EMA, MHRA, PMDA, and every other authority where the product is registered. The lead time spans months and the work has to start during pre-signing.
The electronic Common Technical Document submission identifier transfers with the application. The Newco's regulatory affairs team has to take ownership of the submission archive, the publication infrastructure, and the responses to authority queries from the moment the holder changes. A query from FDA that lands during the transition without a clear owner is a query that will sit on a desk and trigger a deficiency.
Pharmacovigilance reporting under FDA 21 CFR 314.80 and EMA Module VI does not pause for the carve-out. Adverse event reports follow fixed timelines. The Newco needs an operational pharmacovigilance system from sunrise on Day One. Most carve-outs run the safety database under TSA hosting until the destination database is validated and the qualified person for pharmacovigilance has been notified to the relevant authority.
Manufacturing site licences, manufacturing authorisations, and Drug Enforcement Administration registrations all reference the seller as the holder. The transfer requires updates with each authority and a coordinated cutover with the contract manufacturers. Where the carve-out includes a manufacturing site, the site itself has to be relicensed under the Newco. Where the manufacturing stays at the seller's site under the TSA, the supply agreement carries the technical, quality, and intellectual property terms that protect the Newco's product.
Batch record continuity is the second discipline. Every commercial batch and every clinical batch has a master batch record, an executed batch record, a quality control test record, and a release decision. The Newco needs unbroken access to these records from Day One because a recall or a deviation investigation has no margin for confusion about who manufactured what under whose authority.
Supply continuity is the third discipline. Active pharmaceutical ingredient supply, excipient supply, primary packaging, secondary packaging, and cold chain logistics all flow through contracts that need formal assignment to the Newco. Some assign with consent only. Some require a fresh qualification under the Newco's supplier quality management system. The pattern overlaps with the broader carve-out vendor contract assignments playbook.
Life sciences carve outs typically involve significant intellectual property. Patents, trade secrets, know how, regulatory exclusivities, orphan drug designations, and pediatric exclusivities all transfer with the product. The Newco needs a clean chain of title for every patent in scope. Where the seller retains rights in adjacent fields, the field of use definitions in the licence agreements need to be tight enough to avoid future disputes.
Inbound licences from academic institutions, research foundations, and other companies often carry consent requirements for assignment. Each licence has to be reviewed before signing because a non assignable licence may force a renegotiation that changes the economic value of the deal. The licence assignment list should be on the deal team's pre-signing checklist with consent timelines mapped to close.
Trademark transfers and domain transfers follow standard processes but the lead time matters. A Newco that ships product without clear trademark ownership in a market faces a customs hold and a competitor opportunity. The pattern overlaps with the broader TSA intellectual property licensing playbook.
A clean life sciences TSA exit closes three records. The Newco operates a complete quality management system under its own qualified person and management representative. Every validated system runs in the Newco's environment with its own validation evidence. Every regulatory submission, manufacturing licence, and clinical trial authorisation reflects the Newco. The cutover documentation supports the broader TSA exit certificate and the audit committee can rely on a single regulatory perimeter.
Open items, typically a small set of in flight pharmacovigilance signals, ongoing inspections, and clinical trial close out activities started under the seller, are tracked under a short post-close services agreement with a hard end date. The agreement specifies the seller's continued cooperation on legacy investigations, audit support, and document retrieval. An inspection during the post-close window deserves a coordinated response on both sides.
Specialist support across the life sciences carve-out is part of the TSA Pre-Signing Review service when the buyer wants the regulatory exposure quantified before signing. The work coordinates with the Newco's regulatory affairs lead, the head of quality, the head of clinical, the CIO, and the seller's quality, validation, and regulatory teams.
FDA QSR continuity, validated systems, and the disciplined exit ramp.
Read the article →HIPAA boundaries, EHR separation, and the disciplined exit ramp.
Read the article →Plant level cutovers, supplier consents, and the manufacturing TSA exit.
Read the article →The 90-day governance, IT, finance, HR and procurement separation plan we run on live carve-outs. Get the playbook plus the bi-weekly Day One Letter — short, signal-heavy, buyer-side.
No spam. Unsubscribe in one click. · Read the overview first →
Fixed-fee proposal in 48 hours. Senior team on day one. The first conversation is always free.
Seven buyer-side moves to exit a Transition Services Agreement on time and below budget. The mark-up, the extension-fee curve, exit sequencing, and the 11-month calendar.
A representative $90M-revenue life-sciences carve-out runs a Transition Services Agreement across eight functions, every one of them touching a validated system or regulated data. The moves below cut the exit from a 20-month drift to a 12-month managed exit and remove $2.5M of mark-up and stranded cost — while preserving the validated state and data integrity the regulators require.
One tactic, one benchmark, or one pattern from a recent buyer-side engagement. Short. Signal heavy. Free.
Subscribe to The Day One Letter →